未满足的需求和未来的方向在多变性心肌病的治疗
1Department of Cardiology, Heart, Vascular and Thoracic Institution, Cleveland Clinic, USA.
Progress in cardiovascular diseases
|August 10, 2023
概括
缺血性心肌病 (HCM) 是一种遗传性心脏病,需要早期诊断和新的治疗方法. 新兴的治疗方法,如心脏肌酸酶抑制剂和基因编辑,为改变疾病提供了希望.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 超性心肌病 (HCM) 是一种普遍存在的单遗传性疾病,影响大约0.2%的人口.
- 目前的治疗方法可以控制症状,但不能改变疾病的自然进展.
- 由于疾病的高负担,准确的诊断和预防误诊至关重要.
研究的目的:
- 审查最近在HCM的诊断和治疗方面的进展.
- 在当前的HCM管理策略中识别未满足的需求.
- 探索HCM治疗的未来方向,包括新药疗法和基因编辑.
主要方法:
- 关于HCM诊断和治疗的最新进展的文献综述.
- 对新兴药物治疗方法的分析,如心脏肌抑制剂.
- 评价基因编辑技术和新型手术技术用于HCM.
主要成果:
- 新型药物疗法,包括心脏肌抑制剂,正在迅速发展治疗领域.
- 基因编辑显示了纠正HCM遗传基础的希望.
- 新的干预程序为现有的隔膜缩小疗法提供了替代方案.
结论:
- 由于新的医疗和干预选择,HCM的治疗正在迅速发展.
- 基因编辑通过解决其遗传根源,代表了HCM未来的潜在治疗方法.
- 持续的研究和开发对于解决HCM护理的未满足需求至关重要.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Cardiomyopathy I: Introduction and Classification
15
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
15
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K


